SILO

Silo Pharma, Inc. (SILO) Economic Moat Analysis (2026)

Invetso Score: 1.3/10 — Weak · Last Updated: 2026-09-01

Monthly Update

No material changes this month.

Intangible Assets

Score: 1.5 (Weak)

SILO does not appear to possess meaningful brand, patent, or regulatory-intangible protection that would let it sustain pricing power versus peers, so any advantage is not durable.

The absence of disclosed long-run profitability metrics and the deeply negative ROIC/ROCE suggest no evidence of proprietary assets converting into superior returns versus peers.

Compared with peers that have protected formulations, patents, or regulated exclusivity, SILO’s moat from intangible assets looks materially weaker and more replicable.

No filing-based evidence indicates customer willingness to pay a premium for unique intellectual property, which limits retention and margin durability.

Switching Costs

Score:

A TTM ROIC of -91.3% and extremely low asset turnover imply customers are not locked into a high-value workflow that preserves economics versus peers.

There is no evidence of contractual, technical, or compliance-driven lock-in that would make replacement costly for customers relative to alternative suppliers.

Compared with peers that embed products into regulated or mission-critical processes, SILO shows no sign of meaningful switching friction or renewal stickiness.

The negative cash conversion cycle does not indicate customer dependence; instead, it points to weak operating economics that do not reinforce retention.

Network Effects

Score:

SILO shows no observable network effect where more users, data, or counterparties increase the product’s value and create peer-leading retention.

Unlike platform peers with ecosystem-driven adoption, SILO lacks evidence of a self-reinforcing user base that would compound pricing power over 5–10 years.

The available metrics do not show scale-driven engagement or data advantages that would make the business more valuable as usage expands.

Without a visible multi-sided ecosystem, network effects appear absent and therefore do not support moat durability versus peers.

Cost Advantage

Score:

TTM ROIC and ROCE are both deeply negative, which indicates SILO is not converting capital into returns at a level consistent with a structural cost advantage versus peers.

Asset turnover of 0.009x suggests the asset base is not being used efficiently enough to imply lower unit costs or superior operating leverage.

Compared with lower-cost peers, SILO does not show evidence of procurement, manufacturing, or distribution advantages that would protect margins.

The current efficiency profile points to a weaker cost position, so pricing flexibility is unlikely to be durable.

Efficient Scale

Score:

There is no evidence that SILO operates in a market structure where one or two firms can serve demand at materially lower cost than smaller rivals, so efficient scale is not apparent.

The available metrics do not show the kind of high fixed-cost absorption or dominant share that would deter entry and protect returns versus peers.

Compared with peers in concentrated industries, SILO does not appear to benefit from a scale position that would make competition uneconomic.

The lack of demonstrated operating efficiency and the negative return profile suggest scale is not translating into a durable barrier to entry.

Overall Score

Score:

SILO’s moat appears weak versus peers because the available evidence shows no durable intangible assets, switching costs, network effects, cost advantage, or efficient scale, while deeply negative ROIC/ROCE and extremely low asset turnover indicate poor structural protection of margins and retention over the next 5–10 years.

Sources

  • Company filings (10-K, 10-Q, investor presentations)
  • Financial and market data providers
  • Public news and industry information

🔒 Go Beyond This Framework

This is one of 10 institutional-grade frameworks Invetso runs on Silo Pharma, Inc.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

Create your free account on Invetso →